# Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis

_Oncology Research · Karolina Winsko-Szczęsnowicz, Aleksandra Konieczna, Katarzyna Świderska et al. · 2026_

Canonical: https://diginpl.com/books/paper-or-2026-089591
Last updated: 2026-11-10

## Quick facts

- **Author:** Karolina Winsko-Szczęsnowicz; Aleksandra Konieczna; Katarzyna Świderska; Miloš Holánek; Roman Dubiański; Lenka Rušinová; Małgorzata Pieniążek; Anika Pękala ([Crossref](https://doi.org/10.32604/or.2026.089591))
- **Published:** 2026 ([Crossref](https://doi.org/10.32604/or.2026.089591))
- **Publisher:** Tech Science Press ([Crossref](https://doi.org/10.32604/or.2026.089591))
- **Journal:** Oncology Research ([Crossref](https://doi.org/10.32604/or.2026.089591))
- **DOI:** 10.32604/or.2026.089591 ([Crossref](https://doi.org/10.32604/or.2026.089591))

## Questions

**Who wrote Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis?**  
Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis was written by Karolina Winsko-Szczęsnowicz, Aleksandra Konieczna, Katarzyna Świderska, Miloš Holánek.

**When was Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis first published?**  
Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis was first published in 2026.

## Sources

- [Publisher record (DOI, via Crossref)](https://doi.org/10.32604/or.2026.089591)

## Licence and attribution

Open-access publication. Read it free at the publisher: https://doi.org/10.32604/or.2026.089591.

## Cite this page

"Germline <i>BRCA1/2</i> Mutations and Outcomes of First-Line Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer: A CEBCC-101 Biomarker Subanalysis". DigiNepal. Last updated 10 November 2026. https://diginpl.com/books/paper-or-2026-089591. Retrieved 14 November 2026.